Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Armata Pharmaceuticals, Inc. stock logo
ARMP
Armata Pharmaceuticals
$2.08
+4.0%
$1.45
$0.90
$3.42
$75.25M0.8768,964 shs41,952 shs
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
$22.69
-5.5%
$20.77
$10.14
$28.42
$284.69M0.8679,500 shs186,714 shs
Humacyte, Inc. stock logo
HUMA
Humacyte
$2.63
+6.0%
$1.73
$1.15
$9.97
$407.96M1.643.79 million shs4.54 million shs
Nuvectis Pharma, Inc. stock logo
NVCT
Nuvectis Pharma
$9.66
$9.37
$4.44
$11.80
$201.84M-0.11127,640 shs74,092 shs
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Armata Pharmaceuticals, Inc. stock logo
ARMP
Armata Pharmaceuticals
+4.00%-0.95%+47.53%-43.17%-43.17%
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
-5.46%-13.56%+7.89%-4.86%+92.78%
Humacyte, Inc. stock logo
HUMA
Humacyte
+6.05%+12.39%+80.14%-21.96%-64.89%
Nuvectis Pharma, Inc. stock logo
NVCT
Nuvectis Pharma
0.00%-3.88%-9.30%+43.96%+46.81%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Armata Pharmaceuticals, Inc. stock logo
ARMP
Armata Pharmaceuticals
1.8717 of 5 stars
3.53.00.00.01.71.70.0
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
4.426 of 5 stars
4.64.00.04.62.20.80.0
Humacyte, Inc. stock logo
HUMA
Humacyte
2.7206 of 5 stars
3.52.00.00.03.62.50.6
Nuvectis Pharma, Inc. stock logo
NVCT
Nuvectis Pharma
2.9255 of 5 stars
3.50.00.00.03.85.00.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Armata Pharmaceuticals, Inc. stock logo
ARMP
Armata Pharmaceuticals
3.00
Buy$9.00332.69% Upside
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
3.22
Buy$41.8684.47% Upside
Humacyte, Inc. stock logo
HUMA
Humacyte
3.00
Buy$11.71345.41% Upside
Nuvectis Pharma, Inc. stock logo
NVCT
Nuvectis Pharma
3.00
Buy$17.0075.98% Upside

Current Analyst Ratings Breakdown

Latest ARMP, CDTX, HUMA, and NVCT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/27/2025
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$47.00
5/23/2025
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$31.00 ➝ $35.00
5/23/2025
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$35.00
5/19/2025
Armata Pharmaceuticals, Inc. stock logo
ARMP
Armata Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$7.00 ➝ $9.00
5/16/2025
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$35.00 ➝ $50.00
5/14/2025
Humacyte, Inc. stock logo
HUMA
Humacyte
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$4.00
5/14/2025
Humacyte, Inc. stock logo
HUMA
Humacyte
Benchmark
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$17.00 ➝ $14.00
5/13/2025
Humacyte, Inc. stock logo
HUMA
Humacyte
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$25.00 ➝ $25.00
5/9/2025
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$33.00 ➝ $35.00
5/9/2025
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetMarket Outperform ➝ Market Outperform$46.00 ➝ $47.00
4/30/2025
Nuvectis Pharma, Inc. stock logo
NVCT
Nuvectis Pharma
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$11.00 ➝ $15.00
(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Armata Pharmaceuticals, Inc. stock logo
ARMP
Armata Pharmaceuticals
$4.53M16.61N/AN/A($0.89) per share-2.34
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
$302K942.69N/AN/A($1.82) per share-12.47
Humacyte, Inc. stock logo
HUMA
Humacyte
$517K789.10N/AN/A$0.13 per share20.23
Nuvectis Pharma, Inc. stock logo
NVCT
Nuvectis Pharma
N/AN/AN/AN/A$0.70 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Armata Pharmaceuticals, Inc. stock logo
ARMP
Armata Pharmaceuticals
-$69.04M-$1.64N/AN/AN/AN/AN/A-60.91%8/12/2025 (Estimated)
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
-$22.93M-$29.47N/AN/AN/A-289.05%-69.64%-33.73%8/11/2025 (Estimated)
Humacyte, Inc. stock logo
HUMA
Humacyte
-$110.78M-$0.69N/AN/AN/AN/A-942.81%-93.82%8/12/2025 (Estimated)
Nuvectis Pharma, Inc. stock logo
NVCT
Nuvectis Pharma
-$22.26M-$1.13N/AN/AN/AN/A-155.80%-104.02%8/5/2025 (Estimated)

Latest ARMP, CDTX, HUMA, and NVCT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/13/2025Q1 2025
Humacyte, Inc. stock logo
HUMA
Humacyte
-$0.19-$0.10+$0.09$0.28$0.46 million$0.52 million
5/8/2025Q1 2025
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
-$5.45-$1.66+$3.79-$1.66N/AN/A
5/6/2025Q1 2025
Nuvectis Pharma, Inc. stock logo
NVCT
Nuvectis Pharma
-$0.30-$0.27+$0.03-$0.27N/AN/A
3/28/2025Q4 2024
Humacyte, Inc. stock logo
HUMA
Humacyte
-$0.23-$0.16+$0.07-$0.16$0.64 million$7.23 million
3/6/2025Q4 2024
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
-$5.28-$5.38-$0.10-$5.37N/AN/A
3/4/2025Q4 2024
Nuvectis Pharma, Inc. stock logo
NVCT
Nuvectis Pharma
-$0.28-$0.36-$0.08-$0.36N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Armata Pharmaceuticals, Inc. stock logo
ARMP
Armata Pharmaceuticals
N/AN/AN/AN/AN/A
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
N/AN/AN/AN/AN/A
Humacyte, Inc. stock logo
HUMA
Humacyte
N/AN/AN/AN/AN/A
Nuvectis Pharma, Inc. stock logo
NVCT
Nuvectis Pharma
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Armata Pharmaceuticals, Inc. stock logo
ARMP
Armata Pharmaceuticals
N/A
0.19
0.19
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
N/A
3.54
3.54
Humacyte, Inc. stock logo
HUMA
Humacyte
N/A
1.10
1.10
Nuvectis Pharma, Inc. stock logo
NVCT
Nuvectis Pharma
N/A
2.74
2.74

Institutional Ownership

CompanyInstitutional Ownership
Armata Pharmaceuticals, Inc. stock logo
ARMP
Armata Pharmaceuticals
3.57%
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
35.82%
Humacyte, Inc. stock logo
HUMA
Humacyte
44.71%
Nuvectis Pharma, Inc. stock logo
NVCT
Nuvectis Pharma
96.77%

Insider Ownership

CompanyInsider Ownership
Armata Pharmaceuticals, Inc. stock logo
ARMP
Armata Pharmaceuticals
85.50%
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
7.64%
Humacyte, Inc. stock logo
HUMA
Humacyte
5.10%
Nuvectis Pharma, Inc. stock logo
NVCT
Nuvectis Pharma
35.78%
CompanyEmployeesShares OutstandingFree FloatOptionable
Armata Pharmaceuticals, Inc. stock logo
ARMP
Armata Pharmaceuticals
7036.18 million5.25 millionNot Optionable
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
9012.55 million6.51 millionNo Data
Humacyte, Inc. stock logo
HUMA
Humacyte
150155.12 million111.76 millionOptionable
Nuvectis Pharma, Inc. stock logo
NVCT
Nuvectis Pharma
820.89 million12.41 millionNot Optionable

Recent News About These Companies

Why Nuvectis Pharma, Inc. (NVCT) is Surging in 2025
Nuvectis Pharma initiated with a Buy at Maxim

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Armata Pharmaceuticals stock logo

Armata Pharmaceuticals NYSEAMERICAN:ARMP

$2.08 +0.08 (+4.00%)
Closing price 05/28/2025 04:10 PM Eastern
Extended Trading
$2.06 -0.02 (-0.77%)
As of 05/28/2025 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has research collaboration agreement with Merck Sharp & Dohme Corp. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Los Angeles, California.

Cidara Therapeutics stock logo

Cidara Therapeutics NASDAQ:CDTX

$22.69 -1.31 (-5.46%)
Closing price 05/28/2025 04:00 PM Eastern
Extended Trading
$21.96 -0.73 (-3.22%)
As of 05/28/2025 06:07 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cidara Therapeutics, Inc., a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California.

Humacyte stock logo

Humacyte NASDAQ:HUMA

$2.63 +0.15 (+6.05%)
Closing price 05/28/2025 04:00 PM Eastern
Extended Trading
$2.64 +0.02 (+0.57%)
As of 05/28/2025 07:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.

Nuvectis Pharma stock logo

Nuvectis Pharma NASDAQ:NVCT

$9.66 0.00 (0.00%)
Closing price 05/28/2025 04:00 PM Eastern
Extended Trading
$9.66 +0.00 (+0.01%)
As of 05/28/2025 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma. It is also developing NXP900, a small molecule drug candidate, which is in Phase 1a clinical trails that inhibits the Proto-oncogene c-Src and YES1 kinases. It has license agreement with the CRT Pioneer Fund for the NXP800 and any of related derivatives; and the University of Edinburgh for the NXP900 and any of associated derivatives. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.